SCHEMBL1663159

SCHEMBL1663159

Cc1ccc(C(=O)O)n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.44
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
HSD17B10 Q99714 5/20 0.43
HPGD P15428 3/20 0.43
MCL1 Q07820 2/20 0.42
POLB P06746 5/20 0.42
TDP1 Q9NUW8 5/20 0.42
MEN1 O00255 4/20 0.42
MAPT P10636 4/20 0.42
KMT2A Q03164 4/20 0.42
APEX1 P27695 3/20 0.42
NR4A1 P22736 5/20 0.41
HAAO P46952 1/20 0.41
GFER P55789 1/20 0.40
MYC P01106 6/20 0.39
RECQL P46063 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
USP2 O75604 2/20 0.38
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71983 0.85 MCL1 (0.48) KDM4EALDH1A1HSD17B10HPGDMCL1
SCHEMBL9336190 0.83 NAMPT (0.45) NAMPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL10961992 0.79 NAMPT (0.42) NAMPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL5172834 0.76 MCL1 (0.42) KDM4EALDH1A1HSD17B10HPGDMCL1
SCHEMBL13851546 0.76 NAMPT (0.41) NAMPTKDM4EALDH1A1HPGDPOLB
SCHEMBL7707957 0.76 NAMPT (0.41) NAMPTKDM4EALDH1A1HPGDMEN1
SCHEMBL12748885 0.76 NPC1 (0.47) NAMPTKDM4EALDH1A1TDP1MYC
SCHEMBL7706728 0.76 NAMPT (0.41) NAMPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL1529724 0.74 MCL1 (0.46) KDM4EALDH1A1HSD17B10HPGDMCL1
SCHEMBL3277119 0.74 MCL1 (0.41) KDM4EALDH1A1HSD17B10HPGDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101006052-A Pyrrole derivatives as pharmaceutical agents EXELIXIS INC (US) 2007-07-25 CN claimed
CN-1476434-A Novel compounds 2004-02-18 CN claimed
EP-4654964-A1 SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF The Rockefeller University (US) 2025-12-03 EP disclosed
US-12408914-B2 Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials CILAG GMBH INTERNATIONAL (CH) 2025-09-09 US disclosed
EP-4543502-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS Cilag GmbH International (CH) 2025-04-30 EP disclosed
WO-2024261659-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 WO disclosed
US-20240423617-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
US-20240423620-A1 COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
US-20240382613-A1 METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES THE PENN STATE RESEARCH FOUNDATION 2024-11-21 US disclosed
US-20240335540-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES PENN STATE RES FOUND (US) 2024-10-10 US disclosed
CN-118613287-A Compositions and methods for targeted delivery of therapeutic and/or diagnostic substances 宾夕法尼亚州立大学研究基金会 2024-09-06 CN disclosed
EP-1519932-A1 BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY Cyclacel Limited (GB) 2005-04-06 EP disclosed
EP-1466902-A1 ANDROGEN RECEPTOR ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2004-10-13 EP disclosed
CN-1142937-C Antibacterial cephalosporins �Ҵ���˾ 2004-03-24 CN disclosed
CN-1476434-A Novel compounds 2004-02-18 CN disclosed
WO-2004005278-A1 BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY CYCLACEL LIMITED (GB) 2004-01-15 WO disclosed
US-6610730-B2 Viricides; protease inbhibitor AGOURON PHARMACEUTICALS, INC. 2003-08-26 US disclosed
EP-1299357-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2003-04-09 EP disclosed
WO-2001098273-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-12-27 WO disclosed
CN-1186494-A Antibacterial cephalosporins BIOCHEMIE GMBH (AT) 1998-07-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382613-A1 METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES PAICS, APEX1, ADM2 NAMPT 4255/4885KDM4E 3785/4885ALDH1A1 327/4885
US-20240335540-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES PAICS, CD47, CA13 NAMPT 2247/4885KDM4E 3564/4885ALDH1A1 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.